Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Debt (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Non-Current Debt for 6 consecutive years, with $10.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt changed 0.15% to $10.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.0 million, a 0.15% change, with the full-year FY2025 number at $10.9 million, changed 0.17% from a year prior.
  • Non-Current Debt was $10.0 million for Q4 2025 at Aytu Biopharma, down from $10.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $15.0 million in Q4 2023 to a low of $129000.0 in Q4 2021.
  • A 5-year average of $10.3 million and a median of $10.9 million in 2024 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: plummeted 98.7% in 2021, then soared 11165.89% in 2022.
  • Aytu Biopharma's Non-Current Debt stood at $129000.0 in 2021, then skyrocketed by 11165.89% to $14.5 million in 2022, then increased by 3.06% to $15.0 million in 2023, then plummeted by 33.35% to $10.0 million in 2024, then increased by 0.15% to $10.0 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Non-Current Debt are $10.0 million (Q4 2025), $10.4 million (Q3 2025), and $10.9 million (Q2 2025).